Axsome Therapeutics shares 5% surge as second quarter revenue beats expectations

Published 04/08/2025, 12:50
 Axsome Therapeutics shares 5% surge as second quarter revenue beats expectations

NEW YORK - On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) reported second quarter financial results that exceeded analyst expectations, driven by strong performance across its product portfolio.

The company’s shares jumped 5.13% in pre-market trading after the earnings release.

The biopharmaceutical company posted total revenue of $150.04 million for the second quarter of 2025, significantly beating the consensus estimate of $139.31 million. Quarterly losses narrowed to $0.97 per share, better than analysts’ expectations of a $1.06 per share loss. The revenue represents 72% growth YoY and 24% sequential growth compared to the first quarter.

AUVELITY, the company’s treatment for major depressive disorder, led the growth with $119.6 million in net product sales, representing an 84% increase YoY and 24% sequential growth. SUNOSI, for excessive daytime sleepiness, contributed $30 million in net product revenue, up 35% YoY. The newly launched migraine treatment SYMBRAVO, which became available in June, added $0.4 million in initial sales.

"Axsome delivered robust second quarter performance, reflecting strong underlying demand for our life-changing medicines, exacting commercial execution, solid regulatory progress, and continued advancement of our differentiated neuroscience pipeline," said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics.

The company expanded market access for AUVELITY by 28 million new covered lives in the commercial channel, bringing overall payer coverage to approximately 83% across all channels.

Axsome remains on track with its pipeline development, including plans to submit a supplemental New Drug Application for AXS-05 in Alzheimer’s disease agitation in the third quarter of 2025, and an NDA for AXS-12 for narcolepsy in the fourth quarter.

The company ended the quarter with $303 million in cash and cash equivalents, which it believes is sufficient to fund operations until reaching cash flow positivity.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.